An image-guided robotic stereotactic radiosurgery (SRS) system can be used to deliver curative-intent radiation in either 
Introduction
Nonlymphomatous nasal tumors are relatively rare in the dog, representing 1-2% of all canine neoplasms. Those nasal tumors are a heterogeneous group of tumors comprised of various histologic classifications, including mesenchymal tumors and epithelial tumors. 1 Nonlymphomatous tumors tend to act in a locally aggressive manner displaying metastasis late in the course of disease. 2 Because of their location and biologic properties, nasal tumors are difficult to treat, and progressive local disease commonly causes deterioration in quality of life leading to either euthanasia or death. 3, 4 The most common treatment of nasal tumors is daily fractionated megavoltage radiation therapy, which tends to result in better survival times (STs) than either surgery or chemotherapy tocols for canine nonlymphomatous nasal tumors rely on daily fractionation of the total dose. 3, [5] [6] [7] [8] [9] [10] [11] [12] [14] [15] [16] [17] That requires the use of anesthesia for each fraction and despite advances in radiotherapy techniques such as three-dimensional imaging and computerized planning, a substantial volume of normal tissue still receives a considerable dose of radiation. Three-dimensional conformal therapy and IMRT reduce the volume of normal tissue receiving a high dose of radiation, thereby limiting the damage to normal tissues but both still require daily fractionated therapy.
Stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) were developed to deliver a highly concentrated dose of radiation exclusively to the tumor. 19 SRS and SBRT do not The proprietary system a is an image-guided radiosurgery system comprised of a 6 megavolt linear accelerator mounted on a robotic-controlled arm and a treatment room image-guidance system consisting of two ceiling-mounted diagnostic X-ray sources with table-mounted flat panel detectors, which provide two real-time orthogonal set-up views of the patient ( Figure 1 ). Prior to imaging with CT, percutaneously placed fiducial markers are inserted either in or adjacent to the tumor. 22 Digitally reconstructed radiographs from the planning CT are compared with data from the two real-time orthogonal set-up images. The location of the fiducial markers on the digitally reconstructed radiographs is compared with that of the fiducial markers on the two real-time orthogonal set-up images, and proprietary target localization computer software uses those comparison views to accurately position the patient for treatment via automated movements of the treatment couch. 23 Treatment planning was achieved with a proprietary system b that allowed inverse planning and nonisocentric radiation delivery. The total radiation dose to be delivered to the tumor was determined, and boundaries to protect nearby critical structures were defined. That software then determined the targeting positions and the dose to be delivered from each targeting position.
Once the treatment plan was optimized and approved for delivery, the target localization software previously described directed the highly mobile radiation source, which delivered highly collimated beams through multiple paths based on the treatment plan. 22 In typical image-guided robotic SBRT treatment plans, approximately 100-200 beams were delivered via three paths through collimators that ranged in size from 5 mm to 60 mm.
The proprietary radiosurgery system (hardware and software) delivers radiation with submillimeter accuracy. [24] [25] [26] Image guided Stereotactic Body Radiotherapy for Nasal Tumors robotic SBRT has been used extensively for a wide variety of tumors in human medicine, but to the authors' knowledge, this is the first report of the use of image-guided robotic SBRT in dogs.
The purposes of this retrospective study were to evaluate the clinical outcome and prognostic factors influencing survival of dogs with spontaneously occurring nonlymphomatous nasal tumors treated with image-guided robotic SBRT either with or without adjunctive therapy and to report any associated toxicity. Total prescribed dose was based initially on maintaining equivalence to the average biologically effective dose for lateresponding tissues (BED 3 ) in typical daily fractionated radiation therapy protocols. Fraction size is the overriding factor in determining late effects. Specifically, the larger the fraction size, the greater the effect on late-responding tissues. 18 Tolerance levels for late-responding tissues are usually set at TD5/5 meaning that the normal tissue complication probability is , 5% 5 yr after radiation. 27 As radiosurgery uses very high doses/fraction, late-responding tissues are at higher risk than with daily fractionated megavoltage radiation protocols. As such, starting with a conservative radiosurgery dose with a BED 3 equivalent to that of the BED 3 for daily fractionated megavoltage radiation seemed reasonable to ensure that late side effects to those tissues would not exceed a tolerable level. Based on one author's experience (M.W.), that method of calculation is used in the human field when starting doses for either SRS or SBRT are completely unknown.
Materials and Methods
Based on previous studies, as well as the authors' experience, it was decided that a hypothetical daily fractionated megavoltage radiation protocol of 54 Gy given in 3 Gy fractions (hypothetical protocol) was a reasonable starting point to determine a radiosurgery dose. 13, 14, 16 Based on human radiosurgery protocols for tumors in mucosal areas, the authors elected to fractionate the total radiosurgery dose into three fractions. To determine the SBRT radiosurgery dose/fraction that would maintain an equivalent BED 3 to that of the hypothetical protocol, BED 3 was calculated using the following formula:
In that equation, E/a ¼ BED, nd ¼ total dose, and d ¼ dose/ fraction. The published standard value for a/b for late-responding tissues is 3, and that value was used in all calculations reported herein. 18 Using that protocol, the BED 3 for the hypothetical protocol was 108 Gy. The dose/fraction for SBRT was then calculated by iteratively changing d, given that n ¼ 3 until a BED of 108 was produced. Based on that iterative calculation, a SBRT protocol of three consecutive daily fractions of 9 Gy/fraction for a total of 27
Gy would have an equivalent BED 3 to that of the hypothetical protocol.
The time-corrected BED for acute-responding tissues and tumors (BED 10 ) for the hypothetical protocol was 59.6 based on the formula: The physicist (M.W.) and the radiation oncologist (S.C.) involved in planning felt that the proposed protocol of three consecutive day fractions of 9 Gy/fraction for a total of 27 Gy was a reasonable starting dose, especially because it falls within the dose ranges for hypofractionated radiosurgery for head and neck tumors reported in human medicine. 28 The total prescribed dose ranged between 24 Gy and 36 Gy, delivered in three consecutive fractions. The variation in prescribed dose was primarily due to tumor type, with squamous cell carcinomas and anaplastic carcinomas receiving higher doses and either very large tumors or tumors with significant invasion into the brain receiving smaller doses.
Accurate patient set-up was achieved using the image-guided robotic SBRT system imaging and positioning software and hardware as described above. No immobilizers for repositioning (e.g., vacuum-lock bags, jaw immobilizers) were necessary due to the previously placed fiducial markers. Real-time imaging throughout treatment was used to ensure spatial accuracy. The radiation itself was delivered by the robotic arm-mounted linear 
Statistical Analysis
Overall survival analysis was performed by Kaplan-Meier product- For continuous variables, the median was determined, and the values were subsequently grouped into two categories: above the median and below the median. Independent variables were entered in the regression model if the P value was , 0.1. All reported P values were two sided. Values of P # 0.05 were considered significant. Statistical analyses were performed using a commercial software system f .
Results
Nineteen dogs met the criteria for inclusion in the study. There were 13 pure-breed dogs and 6 mixed-breed dogs. The median age of patients was 9 yr (mean, 8.8 yr; range, 4-14.1 yr). There were 11 castrated males, 4 spayed females, and 4 males. Diagnoses included adenocarcinoma (n ¼ 9), carcinoma (not otherwise specified, n ¼ 5), osteosarcoma (n ¼ 1), chrondrosarcoma (n ¼ 2), squamous cell carcinoma (n ¼ 1), and anaplastic sarcoma (n ¼ 1).
All diagnoses were confirmed by histopathology.
Staging was based on CT scanning in all animals. 16 No dogs in the current study experienced grade 2 or higher acute cutaneous toxicity. In this study, 4% of animals experienced grade 1 acute ocular toxicity compared with 35-62% of animals experiencing grade 2 or 3 toxicity with daily fractionated megavoltage radiation. 16 No dog in the current study displayed grade 2 or higher acute ocular toxicity.
Acute side effects were also lower in dogs treated with IMRT than with daily fractionated megavoltage radiation, likely due to the increased conformality. Nonetheless, the IMRT acute side effects were still higher than those reported herein. 16 With image-guided robotic SBRT, not only was the percentage of animals that experienced acute side effects comparatively much lower than that of daily fractionated megavoltage radiation, the severity of the acute effects was significantly less.
The decrease in acute side effects may have been due to the conformality associated with image-guided robotic SBRT, but it may also be due to the lower BED 10 for the image-guided robotic protocol.
Late-term radiation-induced ocular side effects (including cataracts and blindness) and skin side effects (including alopecia, leukotrichia, hyperpigmentation, and fibrosis) have been reported with daily fractionated megavoltage radiation for canine nasal tumors. In the current study, no dogs had late-term ocular effects. The low incidence of late-term grade 3 ocular toxicity compares very favorably with the 3-45% late-term grade 3 ocular toxicity seen with daily fractionated megavoltage radiation. 16 Severe, potentially life threatening, late-term effects are also reported with daily fractionated megavoltage radiation (cobalt 60), including neurologic dysfunction (e.g., seizures) in 13% and osteoradionecrosis in 2-5%. 8 were not an initial complaint were radiation related, which is unlikely, the percentage of animals (16%) with neurologic dysfunction postSBRT was similar to that seen with daily fractionated megavoltage radiation. One patient (5%) developed an oronasal fistula and experienced grade 3 bone toxicity (bone necrosis). In that case, there was a significant oronasal mass effect prior to treatment and it was in that location that the oronasal fistula occurred. A buccal mucosal flap was used to fix the oronasal fistula 3 mo postSBRT. Dehiscence occurred within 1 mo of the flap closure, which appeared to be the result of expansion of the oronasal fistula. It is likely that the full extent of the tumor death and/or necrosis that caused the fistula had not occurred at the time of the surgery because it can take up to 6 mo or more for radiation-associated death of cells to occur.
However, it is uncertain whether surgery for the oronasal fistula would have been successful in any case because radiation can result in a decrease in tensile strength of the mucosa, which might have prevented successful closure. The area of the bone necrosis also had documented regrowth of tumor surrounding the area, and it is difficult to determine whether the necrosis was either radiation or tumor related.
There are limitations associated with this study. The study is retrospective in nature; therefore, the authors are relying on information available in the record, the referring veterinarian's record, and/or owner recollections. The protocols used by different clinicians for staging, restaging, adjuvant therapy, and reporting of side effects varied, which could have impacted the study results, outcomes, and/or reported side effects. In addition, a relatively small number of animals were treated. As such, the fact that there were no independent variables that had a statistically significant effect on survival may be due to either the lack of power or the lack of true association. Last, posttreatment advanced imaging was not routinely performed, making it impossible to accurately assess the disease-free interval, to objectively assess the response to treatment, and to determine if some late-term side effects were tumor-related versus radiation-related.
Based on this study, it appears that any dog with nasal carcinoma or sarcoma is a potential candidate for image-guided 
